“We are living in an era of the most sophisticated technological advances, yet the treatment of cancer is paleolithic” – Azra Raza MD
Adaptive Cancer Therapy: A Paradigm Shift in Cancer Treatment
By Donnie Yance
To picture this new form of cancer therapy, let’s start with a parable. Imagine a field full of weeds where most are tall and leafy, while a few short, scraggly ones hide beneath the taller layer. If someone sprays an herbicide that only kills the tall leafy plants, the field initially looks much cleaner and the job appears done. But lower to the ground, the shorter weeds were never eliminated—they were simply overshadowed. Now that the taller dominant plants are gone, the stubborn short weeds no longer face competition for space and nutrients. Freed from constraint, they spread rapidly and take over the entire field.
This parable mirrors what happens with conventional cancer treatment. The “maximum tolerated dose” (MTD) approach hits tumors as hard as possible to kill the maximum number of cancer cells. While this can produce fast initial responses, it often leads to resistance and treatment failure.
The problem is evolutionary: aggressive chemotherapy eliminates drug-sensitive cells (the tall leafy weeds), allowing pre-existing resistant cells (the short stubborn weeds) to proliferate unchecked through a process called “competitive release.”
The term “competitive release” can be confusing if taken literally. It sounds like something physical is being released, but actually it’s a term from ecology that refers to the release of the pressure of competition from a group of organisms.
A similar logic can be seen in geopolitical strategy, where a force may navigate a pragmatic, indirect alignment with an adversary to suppress an even more dangerous shared threat. In Afghanistan, for instance, the United States found occasional, tacit overlap with the Taliban in combating ISIS-K. This was not a formal alliance or an endorsement of the Taliban, but rather a calculation that their presence helped exert pressure on a far more volatile and destructive extremist faction.
This principle of competitive containment forms the foundation of adaptive cancer therapy. Conventional cancer treatment often relies on MTD strategy, attacking tumors with the highest possible force to eliminate the greatest number of cells. While this approach can produce dramatic initial responses, entirely wiping out treatment-sensitive cells eliminates the natural competition that keeps dangerous, drug-resistant cells in check. By contrast, adaptive therapy aims to maintain a stable, manageable population of original, sensitive cancer cells—using them as a biological buffer to outcompete and suppress the growth of far more aggressive, treatment-resistant variants.
Adaptive therapy represents a fundamentally different strategy. Instead of trying to eradicate all cancer cells, it aims for long-term disease control by exploiting the competitive dynamics between drug-sensitive and drug-resistant tumor populations. The approach works by:
- Modulating treatment timing and dosage based on tumor response rather than fixed schedules
- Maintaining a population of treatment-sensitive cells that compete with and suppress resistant cells
- Using treatment breaks strategically to allow sensitive cells to outcompete resistant ones during drug-free periods
- Reducing cumulative drug exposure while extending progression-free survival
The underlying principle is elegant: resistant cells pay an energetic cost to maintain their resistance mechanisms. When treatment is paused, this becomes a disadvantage, and sensitive cells regain their competitive edge.
Competitive release in a tumor. Before treatment (left), the sensitive cells dominate the tumor, with a smaller pre-existing resistant sub-population. Chemotherapy kills off most of the sensitive cells (middle), thus selecting for the resistant strain. The relative fitness of the landscape has changed, and the chemo-resistant cells flourish (right), rendering the subsequent rounds of treatment less effective.
The Challenge of Non-Genetic Resistance
While this new treatment may seem like a perfect situation, adaptive therapy faces a significant challenge: non-genetic resistance mechanisms can rapidly shift tumor populations toward resistance without requiring genetic mutations. Three key mechanisms threaten adaptive therapy’s effectiveness:
- Tumor Microenvironment Protection — The connective tissue surrounding tumors creates physical and chemical barriers that shield cancer cells from chemo, independent of the cells’ intrinsic drug sensitivity.
- Epithelial-to-Mesenchymal Transition (EMT) — Cancer cells can temporarily change their form to act more like stem cells, which makes them harder to kill. They can even become resistant to multiple drugs within just 1–2 days of treatment.
- Drug Efflux Pump Transfer — Resistance proteins can be rapidly shared between cells via extracellular vesicles, spreading resistance horizontally across the tumor population without requiring cell division or genetic change.
These mechanisms can quickly expand the resistant population at the expense of sensitive cells, undermining adaptive therapy’s ability to maintain controllable tumor dynamics.
Mederi Care and Unitive Medicine: A Complementary Approach
“Wisdom is a state of being. Knowledge is a function of action put into motion. Where wisdom infuses knowledge, then the heart, mind and body become instruments of truth.”
– David LaChapelle
Mederi Care (also known as the Eclectic Triphasic Medical System) represents the art and science of integrated medicine, encompassing all domains of healthcare. It draws upon the cumulative clinical experience and time-tested integration of traditional medical systems, modern medicine, and the latest advances in scientific research. Mederi Care is guided by a singular commitment to patient outcomes, making individualized treatment decisions based on what is in each patient’s best interest. The ultimate goals are to help patients achieve an improved quality of life and increased longevity.
Traditional herbal medicine represents a foundational component of Mederi Care’s integrated philosophy and spiritual perspective. The philosophy’s roots are grounded in the motto “sustain the life force” and the commitment to enhance vitality.
This unique model provides a framework for developing novel therapeutic strategies while incorporating the best of holistic and conventional medicine supported by the latest scientific research at the molecular, cellular, and genomic levels.
The Mederi Care model is not focused merely on attacking the cancer without examining the factors that allowed the cancer to arise in the first place. Practitioners develop personalized and comprehensive treatment plans based on thorough assessment and utilization of botanical, nutritional, dietary, and lifestyle medicine, often with guidance regarding conventional pharmaceutical medicine.
This approach embodies unitive medicine—a philosophy that treats the person as an integrated whole rather than separating mind, body, and spirit. Unitive medicine is genuinely integrative when practiced at the highest level, requiring practitioners to cultivate perceptual and treatment skills that bring this unified approach to patients.
How Herbal Medicine Addresses Non-Genetic Resistance
Emerging research suggests herbal medicine may provide precisely the tools needed to counter the non-genetic resistance mechanisms that challenge adaptive therapy:
Bioactive compounds from medicinal plants—including flavonoids, alkaloids, terpenoids and polyphenols— induce apoptosis, inhibit cell proliferation, interfere with microtubule formation, inhibit angiogenesis, modulate key signaling pathways, improve the tumor microenvironment, reverse drug resistance, and activate immune cells.
Experimental evidence suggests that herbal extracts and specific herbal compounds combined with anticancer drugs have the potential to weaken drug resistance to cancer therapy. Herbal compounds can reduce resistance against cancer therapies, which has become a critical concern.
Modulating the Tumor Microenvironment
Herbal anti-cancer therapies offer many benefits, particularly selective toxicity against cancer cells, reducing the adverse side effects associated with conventional chemotherapy. By targeting the tumor microenvironment rather than just the cancer cells themselves, these compounds may help overcome the protective effects of the connective tissue barriers that shield tumors during treatment.
Research is now clear that high dose chemotherapy, and radiation therapy for that matter, not only doesn’t get rid of cancer stem cells (CSCs), it causes them to become more robust, aggressive, and resistant to future therapies.
CSCs are a tumor subpopulation whose capacity for self-renewal, differentiation and proliferation generates unfavorable patient outcomes, including therapeutic resistance and metastasis. Increasingly, specific treatment plans based on identification of molecular features and biomarkers of a patient’s cancer, rather than classification according to tissue origin or bulk tumor properties, are leading to better patient outcomes. Identification of CSC markers has the potential to enhance therapeutic treatments, especially for recurring cancers.
Factors such as increased activation of drug-efflux pumps, enhanced capacity of DNA damage repair, dysregulation of growth and developmental signaling pathways, alterations of cellular metabolism, environmental niche, and impaired apoptotic response are attributed to cancer stem cells in their resistance to the adjuvant chemoradiotherapy to cancer.
CSC-related malignant tumor behavior. CSCs are cells in tumors that can self-renew and generate heterogeneous tumor cells, such as breast cancer and gastric cancer. The presence of CSCs promotes tumorigenesis, growth, metastasis, EMT, drug resistance, and recurrence.
Supporting Immune Function and Reducing Inflammation
Plant-based medicines play an important role in cancer care by helping regulate the immune system. They act as natural boosters that wake up and strengthen the body’s defense cells that fight tumor growth and spread. This kind of immune support can be especially helpful during treatment breaks in adaptive therapy plans.
Herbal extracts and formulations are being studied as supplemental therapies for chemotherapy and/or radiotherapy against a variety of cancers.
Phytochemical mechanisms of action of chemopreventive botanical agents
In cancer, major plant molecules produce signal transduction pathways that control cell death through autophagy and apoptosis. Individually, these phytoconstituents have been shown to stimulate the intrinsic and extrinsic apoptotic pathways by disrupting mitochondrial-caspase-9 and FASligand-caspase-8 arbitrated apoptotic cell death. Phytoconstituents cause both ER stress as well as apoptotic cell death. Several phytoconstituents, however, influence mitochondrial biogenesis and confirm apoptosis-autophagic cell death. In cancer cells, phytoconstituents control the cell cycle and microRNA then causes apoptosis or autophagic cell death. On the other hand, many phytochemicals stimulate autophagic signaling while inhibiting cell growth and autophagy.
Enabling Lower Chemotherapy Doses
The goals of including natural compounds with cancer chemotherapy are to widen the therapeutic window of the chemo drugs and to decrease the occurrence of chemotherapy resistance. Select phytochemicals are capable of both enhancing therapeutic efficacy and reducing side effects for cancer patients.
This synergy aligns perfectly with adaptive therapy’s goal of using minimum effective doses; herbal medicines may allow even lower chemotherapy doses while maintaining tumor control and slowing the emergence of resistant phenotypes.
Clinical Promise and Future Directions
Early clinical trials show promising results. In metastatic prostate cancer, adaptive therapy extended median time to progression from 14 months to 34 months compared to standard treatment, while using only 47% of the cumulative drug dose. Similar benefits have been observed in preclinical models of breast cancer, melanoma, and ovarian cancer.
The integration of herbal medicine with adaptive therapy represents an unexplored frontier with significant potential. Natural compounds from traditional herbal medicine exhibit anti-cancer activities including anti-proliferative, pro-apoptotic, anti-metastatic, anti-angiogenic, as well as regulating autophagy, reversing multidrug resistance, balancing immunity, and enhancing the effectiveness of chemotherapy in vitro and in vivo.
Evidence shows that herbal medicine can be used not only to prevent cancer but also to treat it, and because of their pharmacological safety, these agents can be used alone or as adjuncts to current chemotherapeutic agents to enhance therapeutic effects and minimize chemotherapy-induced toxicity.
Future improvements may come from:
- Combining adaptive therapy protocols with targeted herbal formulations that address specific resistance mechanisms like Epithelial-mesenchymal transition (EMT), drug efflux pumps, and stromal protection
- Using botanical immunomodulators during treatment breaks to keep the remaining sensitive cancer cells and the immune system strong enough to control or suppress the stubborn drug-resistant cells
- Developing standardized herbal extracts with validated effects on tumor microenvironment and drug resistance pathways
The Mederi Care model demonstrates that this approach has repeatedly had astounding results, applied both singularly and in tandem with modern cancer treatments. By combining adaptive therapy’s evolutionary wisdom with herbal medicine’s multi-targeted, low-toxicity approach, we may significantly extend disease control while improving quality of life, thus transforming cancer treatment from an all-or-nothing eradication mission to sustainable chronic disease management.
Conclusion
“The only sure weapon against bad ideas is better ideas.” Alfred Whitney Griswold
Adaptive cancer therapy is not about destroying every cancer cell at all costs, instead it’s about working with the body’s biology to keep the disease under control for as long as possible. Instead of only wiping out the easy-target cells and accidentally giving the drug-resistant ones room to grow, this method uses strategic pauses and lower doses to maintain a balance where sensitive cells help suppress the tougher more resistant ones.
However, non-genetic resistance methods like EMT shifts, drug efflux pumps, and protection from the tumor microenvironment can still undermine this strategy. That’s where herbal medicine may offer a powerful advantage. Plant-based compounds have the unique ability to target multiple resistance pathways at once while also strengthening the immune system and reducing inflammation. When used during treatment breaks, they can provide extra support to keep the stubborn drug-resistant cancer cells from taking over.
The future of cancer treatment may not rely on a single “magic bullet,” but rather on intelligent combinations merging adaptive therapy’s evolution-based strategy with the broad, supportive power of botanical medicine. By shifting from an all-out war to a long-term management approach, we have the potential not only to extend survival, but also to improve quality of life. In many ways, this is not just a new treatment method, it’s a whole new approach to Unitive healing.
